Clinical trials increasingly funded by pharma industry
December 17, 2015Research and Development JAMA, Journal of the American Medical Association, NIH, National Institutes of Health, clinical trials, clinicaltrials.gov, pharma, research
The number of clinical trials funded by pharma has risen significantly since 2006, while the number funded by the US …
AstraZeneca to buy majority share in Acerta Pharma
December 17, 2015Sales and Marketing Acerta Pharma, AstraZeneca, acalabrutinib, acquisitions, mergers
Following several days of speculation, AstraZeneca has announced that it has agreed a deal to buy Acerta Pharma, a developer …
Valeant hires attorney and crisis management firm to handle bad US PR
December 17, 2015Medical Communications, Sales and Marketing Robert Kelner, Valeant, Vianovo. Covington & Burling
Valeant has retained attorney Robert Kelner, a partner at the law firm Covington & Burling, to help the beleaguered pharma …
US ‘star’ Bradner to head Novartis Institute of Biomedical Research
December 17, 2015Research and Development James Bradner, Jay Bradner, Mark Fishman, Novartis, Novartis Institute for Biomedical Research
Novartis has hired James ‘Jay’ Bradner, from Harvard’s Dana-Farber Cancer Institute, to head its Institutes for Biomedical Research from 1 …
Gilead’s Sovaldi wins Drug Discovery of the Year Award
December 16, 2015Research and Development British Pharmacological Society, Gilead, Gilead Sciences, hepatitis C, sofosbuvir, sovaldi
Gilead Science’s hepatitis C treatment Sovaldi has been awarded the British Pharmacological Society’s prestigious Drug Discovery of the Year 2016. …
Archbishop of York to become patron of national charity tackling superbugs
December 16, 2015antibiotic resistance
Antibiotic Research UK (ANTRUK), a charity founded in 2014 to save modern medicine from the onslaught of superbugs, has announced …
MSD UK appoints Jessica Fine as executive director of external affairs
December 16, 2015Medical Communications Jessica Fine, MSD
MSD has appointed former Lexington Health boss Jessica Fine to lead its external affairs team in the UK from April …
New final NICE guidance on AbbVie, BMS, Pfizer and Roche drugs
December 16, 2015Sales and Marketing BioMarin Pharma, Enbrel, Humira, Ikervis, MPS IVa, NICE, NICE guidance, Orencia, RoActemra, Santen, apremilast, ciclosporin, dry eye syndrome, juvenile idiopathic arthritis, otezla, psoriatic arthritis, vimizin
NICE has published final guidance on several drugs, approving therapies for juvenile idiopathic arthritis, dry eye disease and Morquio A …
Avacta appoints Tony Gardiner as chief financial officer
December 16, 2015Medical Communications Avacta Group
Avacta Group, the developer of Affimer biotherapeutics and research reagents, has appointed Tony Gardiner as group chief financial officer. Gardiner …
Analysts say pharma R&D returns challenged by drag of high costs
December 16, 2015Research and Development, Sales and Marketing R&D, drug development, research and development, return of investment, sales, sales forecasts
The projected rate of return on pharma industry research and development has more than halved since 2010, from 10.1% to …
Juan Luciano appointed to Eli Lilly board
December 16, 2015Medical Communications Eli Lilly
The board of directors of Eli Lilly has elected Juan Luciano as a new member, effective February 1 2016. Luciano …
AstraZeneca to acquire Takeda’s respiratory franchise
December 16, 2015Manufacturing and Production, Research and Development AstraZeneca, China, Takeda, investment, respiratory
AstraZeneca and Takeda have agreed a multi-million pound deal for AZ to acquire the Japanese firm’s core respiratory business, including …
Pharma deals crucial to cutting R&D costs
December 16, 2015Research and Development GlobalData, R&D, drug development, pharma, research and development
With the average cost of getting a novel drug to market at almost $2.5 billion, and few products achieving blockbuster …
Pharma companies warned on patent box changes
December 16, 2015Research and Development R&D, patent box, pharma, research and development, tax
Proposed Government changes to legislation will require businesses to track and trace all R&D expenditure if they want to continue …
More breakthroughs in cancer pose the question: Who pays for them?
December 16, 2015Research and Development Cancer, drug access, immunotherapy, oncology
The molecular revolution over the last decade has done much to help turn cancer into an illness that can be …
NICE rejects BMS cancer drug in draft guidance
December 16, 2015Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, NHS, NICE, lung cancer, nivolumab, non small cell lung cancer, non-small cell lung cancer, opdivo
In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic …
NICE says no to NHS funding for Kadcyla
December 16, 2015Research and Development, Sales and Marketing Breast Cancer Now, Kadcyla, NHS, NICE, Roche, advanced breast cancer, breast cancer
NICE has turned down Roche’s application for NHS funding for Kadcyla as a treatment for a type of advanced breast …
Precious Cells Group appoints David Huse in expansion push
December 15, 2015Medical Communications, Research and Development Stem cells, precious cells group
Precious Cells Group, a UK-based international provider of stem cell storage and related technologies, has announced the appointment of commercial …
Amgen buys back rights to three drugs from GSK
December 15, 2015Research and Development, Sales and Marketing Amgen, GSK
Amgen has announced that it will reacquire the rights to three products in 48 countries from GSK, as it seeks …
AstraZeneca invests £75m to future-proof production facilities
December 15, 2015Manufacturing and Production AstraZeneca, manufacturing, production
AstraZeneca says it will invest £75m to future-proof a key production facility in Macclesfield, Cheshire. The upgrade to the 48-year-old …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
